Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Conditioning intensity and genomics: relapse after allogeneic transplant in MDS

Christopher Hourigan • 16 Jun 2020
EHA 2020
Myelodysplastic Syndromes
BMT CTN 0901

Christopher Hourigan, DM, DPhil, FACP, FRCP, of the National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, discusses the impact of conditioning intensity and genomics on relapse after allogeneic transplantation for patients with myelodysplastic syndrome (MDS) as evaluated in the BMT CTN 0901 study (NCT01339910). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Christopher Hourigan

1:39
How can MRD guide treatment of AML?
Christopher Hourigan • 4 Jun 2022
1:11
Current role of MRD in AML
Christopher Hourigan • 4 Jun 2022
1:09
Pre-MEASURE: patients with AML in complete remission but high risk of relapse following alloHCT
Christopher Hourigan • 4 Jun 2022
2:34
Proteomic profiling of bone marrow in AML
Christopher Hourigan • 16 Jun 2020

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024
1:21
HMAs for MDS- a party of one
Guillermo Garcia-Manero • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals